A breakthrough in the field of antibiotic discovery

In 1995, we discovered and developed an effective natural antimicrobial formulation with broad spectrum bactericidal activity against both Gram-negative and Gram-positive bacteria and fungicidal activity against Candida albicans. Its bactericidal activity has shown to be more potent against clinical isolates of beta-hemolytic Streptococcus pyogenes (killing 7.2 X 10⁵ viable cells per ml in 5 minutes, in vitro). Gargling with a solution of the formulation had shown to cure sore throat in human volunteers, and its topical use had cured jock itch, ringworm, staphylococcal and yeast infections and cold sores). It can be an effective treatment for life threatening Streptococcal infections, such as Flesh Eating Disease and Streptococcal Toxic Shock Syndrome, against which no antibiotic can act fast enough to save patient’s life or prevent amputation. It can also shorten treatment duration of non-life threatening Streptococcal infections to barely a few days, as compared to 1-2 weeks with other existing antibiotics (Streptococcus pyogenes is reported to cause 700 million infections around the world annually). This formulation has also demonstrated potent bactericidal activity against Aeromonas hydrophila, Bacillus cereus, E. coli (O:157, O:111 and O:121), Listeria monocytogenes, Proteus vulgaris, Salmonella enteritidis, Salmonella typhimurium, Shigella sonnei, Staphylococcus aureus, Streptococcus epidermidis, Yersinia enterocolitica (O:3) and Serratia liquefaciens, and fungicidal activity against Candida albicans and Saccharomyces cerevisiae and also has saved the lives of two critically ill hospitalized patients with untreatable C. difficile infection and necrotizing cellulitis while other antibiotics were of little or no help. Further detail of experimental studies data on its antimicrobial activity against clinical isolates of Beta-hemolytic Streptococcus pyogenes, Staphylococcus aureus and Candida albicans, and testimonials from users can be accessed upon request.

The WHO stresses an urgent need for new antibiotics. A $1.2 billion development cost per antibiotic and the possibility of its failure due to microbial resistance deters drug companies to invest in the development of new antibiotics and limits the prospect of a new affordable antibiotic entering the market in the near future. Scientists have been exploring the therapeutic potential of combined existing antibiotics, natural and synthetic peptides, bacteriophages, neolactoferrin and Irresistin, however, no new antibiotic for the treatment of Gram-negative bacterial infections has entered the market in the last 30 years. With a 25 years history of efficacy, safety and human use, we are confident that our natural formulation has a great potential to enter the market especially for the treatment of life threatening Streptococcal infection such as flesh eating disease. We are looking forward to collaborate with companies and countries that are interested in our formulation/s and technology of its manufacturing. Interested parties please contact us by mail or e-mail.